

Torsten Kessler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1282974/torsten-kessler-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

1,934

citations

25

h-index

42

g-index

97

ext. papers

2,145

ext. citations

4.8

avg, IF

3.88

L-index

#	Paper	IF	Citations
83	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101942	2.2	1
82	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.. <i>Blood Advances</i> , 2022 ,	7.8	2
81	Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1930-1939	1.9	
80	Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. <i>European Journal of Cancer</i> , 2021 , 150, 143-154	7.5	3
79	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. <i>European Journal of Cancer</i> , 2021 , 151, 150-158 ⁵	7.5	5
78	Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 192, 494-503	4.5	3
77	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 255-262	13.4	5
76	Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021 , 192, e148-e151	4.5	2
75	Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1907-1915	3	2
74	First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. <i>Cancers</i> , 2020 , 12,	6.6	6
73	Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma. <i>PLoS ONE</i> , 2020 , 15, e0229271	3.7	2
72	Aneurysmal bone cyst inadvertently treated with chemotherapy-A series of three cases. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28638	3	3
71	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). <i>BMJ Open</i> , 2020 , 10, e035546	3	3
70	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 2830-2841	10.7	19
69	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). <i>Annals of Hematology</i> , 2019 , 98, 1393-1401	3	6
68	Core Data Elements in Acute Myeloid Leukemia: A Unified Medical Language System-Based Semantic Analysis and ExpertsTReview. <i>JMIR Medical Informatics</i> , 2019 , 7, e13554	3.6	5
67	Blood clot removal by cryoextraction in critically ill patients with pulmonary hemorrhage. <i>Journal of Thoracic Disease</i> , 2019 , 11, 4319-4327	2.6	8

66	Postoperative Complications and Long-Term Results after Primary Cardiac Sarcoma Resection. <i>Thoracic and Cardiovascular Surgeon</i> , 2018 , 66, 637-644	1.6	4
65	An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. <i>Leukemia</i> , 2018 , 32, 510-519	10.7	6
64	Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. <i>Translational Oncology</i> , 2018 , 11, 1271-1282	4.9	14
63	Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases. <i>PLoS ONE</i> , 2018 , 13, e0197315	3.7	3
62	Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible. <i>Blood</i> , 2018 , 132, 5176-5176	2.2	7
61	Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature. <i>European Journal of Haematology</i> , 2017 , 99, 91-100	3.8	9
60	CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. <i>Lung Cancer</i> , 2017 , 113, 121-127	5.9	11
59	Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. <i>Cancer Research and Treatment</i> , 2017 , 49, 548-552	5.2	28
58	Potential therapeutic impact of CD13 expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017 , 12, e0173146	3.4	16
57	Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 443-5	4.4	41
56	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. <i>PLoS ONE</i> , 2016 , 11, e0160871	3.7	7
55	Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. <i>Oncotarget</i> , 2016 , 7, 82458-82472	3.3	13
54	NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. <i>Oncotarget</i> , 2016 , 7, 6774-89	3.3	14
53	Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision. <i>PLoS ONE</i> , 2016 , 11, e0155398	3.7	14
52	Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. <i>Leukemia Research</i> , 2015 , 39, 739-48	2.7	11
51	Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. <i>Bone Marrow Transplantation</i> , 2015 , 50, 485-92	4.4	17
50	Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease. <i>Annals of Hematology</i> , 2015 , 94, 1241-3	3	4
49	Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR. <i>Molecular Pharmaceutics</i> , 2015 , 12, 3749-58	5.6	11

48	Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases. <i>PLoS ONE</i> , 2015 , 10, e0122974	3.7	
47	Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. <i>Cancer Immunology Research</i> , 2015 , 3, 547-56	12.5	36
46	Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. <i>Oncology Letters</i> , 2014 , 8, 1912-1918	2.6	56
45	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. <i>Annals of Hematology</i> , 2013 , 92, 1041-8	3	14
44	Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 2337-47	8.3	20
43	Dexabeam versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T-cell lymphoma: A retrospective evaluation of parallel patient cohorts of one center.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8548-8548	2.2	
42	Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. <i>Respiratory Medicine</i> , 2012 , 106, 1509-16	4.6	19
41	Retrospective Analysis of the Blood Component Utilization in a University Hospital of Maximum Medical Care. <i>Transfusion Medicine and Hemotherapy</i> , 2012 , 39, 129-138	4.2	20
40	Fulminant invasive pulmonary mucormycosis with <i>Rhizopus oryzae</i> in a patient with severe aplastic anaemia and common variable immunodeficiency. <i>Mycoses</i> , 2012 , 55, e32-5	5.2	3
39	Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. <i>Annals of Oncology</i> , 2012 , 23, 990-6	10.3	32
38	High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1321-5	4.4	3
37	Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. <i>Blood</i> , 2012 , 119, 5215-20	2.2	47
36	Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab Activity Against Mantle Cell Lymphoma in Mice. <i>Blood</i> , 2012 , 120, 3716-3716	2.2	1
35	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. <i>American Journal of Hematology</i> , 2011 , 86, E61-4	7.1	18
34	Mixed response in interim positron emission tomography/computed tomography leads to detection of a gastrointestinal stromal tumor in a patient with mediastinal diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, e215-7	2.2	
33	Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. <i>Recent Results in Cancer Research</i> , 2010 , 180, 51-81	1.5	46
32	Tissue-factor fusion proteins induce occlusion of tumor vessels. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S143-50	8.2	29
31	Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. <i>International Journal of Oncology</i> , 2010 , 37, 1389-97	4.4	7

30	Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 335-335	2.2	1
29	Compounds in clinical Phase III and beyond. <i>Recent Results in Cancer Research</i> , 2010 , 180, 137-63	1.5	16
28	Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. <i>Blood</i> , 2009 , 113, 5019-27	2.2	104
27	Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2009 , 124, 1535-44	7.5	15
26	Expression of Osteopontin in the Bone Marrow of Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 4694-4694	2.2	
25	Targeting Tissue Factor to Tumor Vessels. Experimental Results and First-in-Man Experience.. <i>Blood</i> , 2009 , 114, 469-469	2.2	
24	Generation of fusion proteins for selective occlusion of tumor vessels. <i>Current Drug Discovery Technologies</i> , 2008 , 5, 1-8	1.5	29
23	Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. <i>Leukemia Research</i> , 2008 , 32, 491-4	2.7	11
22	Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. <i>Leukemia</i> , 2007 , 21, 1901-6	10.7	49
21	Angiogenesehemmung in der Onkologie. <i>Onkologe</i> , 2007 , 13, 20-31	0.1	
20	Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. <i>Radiology</i> , 2007 , 244, 449-56	20.5	52
19	Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. <i>Investigative Radiology</i> , 2007 , 42, 791-6	10.1	21
18	Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. <i>Current Drug Targets</i> , 2007 , 8, 257-68	3	42
17	Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma. <i>European Journal of Cancer</i> , 2006 , 42, 1904-11	7.5	34
16	Expression of Angiopoietins and Their Receptor Tie2 in the Bone Marrow of Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 1894-1894	2.2	1
15	Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. <i>Haematologica</i> , 2006 , 91, 1203-11	6.6	49
14	Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. <i>Clinical Cancer Research</i> , 2005 , 11, 6317-24	12.9	61
13	Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature.. <i>Blood</i> , 2004 , 104, 1934-1934	2.2	

12	Toll-Like Receptor 3 Is a Mediator of the Innate Immune Response to Cytomegalovirus in Immature Dendritic Cells.. <i>Blood</i> , 2004 , 104, 731-731	2.2	1
11	Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2003 , 10, 1915-7	3.5	8
10	Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. <i>Cancer Research</i> , 2003 , 63, 7241-6	10.1	39
9	Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. <i>Leukemia</i> , 2002 , 16, 1302-10	10.7	160
8	Efficacy and safety of thalidomide in patients with acute myeloid leukemia. <i>Blood</i> , 2002 , 99, 834-9	2.2	78
7	Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 119-24	11.5	120
6	Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. <i>Molecular Therapy</i> , 2001 , 3, 319-22	11.7	109
5	Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). <i>Journal of the American Chemical Society</i> , 2001 , 123, 1280-8	16.4	62
4	Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 12227-32	11.5	127
3	Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study. <i>Leukemia</i> , 1998 , 12, 586-92	10.7	48
2	Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. <i>European Journal of Pharmacology</i> , 1995 , 290, 163-7		29
1	Thalidomide for the Treatment of Acute Myeloid Leukemia		9